188 related articles for article (PubMed ID: 33978203)
1. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
[TBL] [Abstract][Full Text] [Related]
2. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
4. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
7. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
8. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
12. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
15. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
16. Implications of tumor location on subtypes of medulloblastoma.
Teo WY; Shen J; Su JM; Yu A; Wang J; Chow WY; Li X; Jones J; Dauser R; Whitehead W; Adesina AM; Chintagumpala M; Man TK; Lau CC
Pediatr Blood Cancer; 2013 Sep; 60(9):1408-10. PubMed ID: 23512859
[TBL] [Abstract][Full Text] [Related]
17. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
18. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
19. Clinical and mutational profiles of adult medulloblastoma groups.
Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
[TBL] [Abstract][Full Text] [Related]
20. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
